Press releases September 15, 2020 Compass Therapeutics, Inc. Provides Corporate Update August 24, 2020 Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models June 23, 2020 Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement March 30, 2020 Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137 February 28, 2020 Compass Therapeutics to Present at the 40th Cowen Health Care Conference January 6, 2020 Compass Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
